8-K: NeuroPace Reports Strong Q3 2024 Results, Raises Full-Year Revenue Guidance

NeuroPace announced a 28% year-over-year revenue increase in Q3 2024, reaching $21.1 million, and raised its full-year revenue guidance to $78-$80 million.

Summary

• NeuroPace reported a record revenue of $21.1 million for the third quarter of 2024, a 28% increase compared to the same period in 2023.
• The company's revenue growth was primarily driven by increased sales of the RNS System.
• Gross margin for the quarter was strong at 73.2%, within the company's guided range of 72-74%.
• Cash burn decreased to $1.8 million in Q3 2024, compared to $2.3 million in Q3 2023, demonstrating improved operating discipline.
• NeuroPace raised $2.9 million in net cash proceeds through its at-the-market (ATM) offering program.
• The company's cash and short-term investments increased to $56.8 million at the end of Q3 2024.
• Full-year 2024 revenue guidance was increased to $78 million to $80 million, representing a 19% to 22% growth over 2023.
• Total operating expenses for the full year are expected to range between $80 million and $84 million, including approximately $10 million in stock-based compensation.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved cash burn, increased guidance, and positive clinical data. The company's performance and future outlook are encouraging for investors.

Positives

• The company experienced a significant increase in revenue, driven by RNS System sales.
• NeuroPace demonstrated strong gross margin performance.
• The company has shown improved operating discipline by reducing cash burn.
• The company has strengthened its management team with key appointments.
• The company has a strong cash position of $56.8 million.
• The company has increased its full-year revenue guidance.
• The company has submitted positive safety and effectiveness data for the RNS System.

Negatives

• Total operating expenses increased to $19.7 million in Q3 2024, compared to $18.2 million in the same period of the prior year.
• The company reported a net loss of $5.5 million for the third quarter of 2024.
• Long-term borrowings totaled $59.3 million as of September 30, 2024.

Risks

• The company faces uncertainties related to market acceptance and adoption of the RNS System.
• There are risks related to the pricing of the RNS System and availability of adequate reimbursement.
• The company relies on third-party contractors and suppliers.
• Regulatory compliance and approvals are needed to expand the market for the RNS System.

Future Outlook

NeuroPace expects full-year 2024 revenue to range between $78 million and $80 million, representing a 19% to 22% growth over 2023. The company anticipates continued growth driven by increased sales of the RNS System and DIXI Medical products. They also plan to expand access to RNS therapy through Project CARE and new indications for use.

Management Comments

• Joel Becker, Chief Executive Officer of NeuroPace, stated he is very pleased with the company's performance in the third quarter, both with regard to record revenue and a further reduction in cash burn.
• Management believes they have strengthened their leadership team to further capitalize on momentum and position NeuroPace to take full advantage of opportunities.

Industry Context

The announcement reflects a positive trend in the medical device industry, particularly in the neurostimulation sector, where companies are focusing on innovative solutions for chronic conditions like epilepsy. NeuroPace's growth is indicative of the increasing adoption of personalized, brain-responsive therapies.

Comparison to Industry Standards

• NeuroPace's 28% year-over-year revenue growth in Q3 2024 is strong compared to other medical device companies in the neurostimulation space, such as Medtronic and Boston Scientific, which typically see single-digit growth rates.
• The gross margin of 73.2% is also competitive, aligning with industry benchmarks for medical device companies with proprietary technology.
• The reduction in cash burn from $2.3 million to $1.8 million demonstrates improved financial discipline, which is a positive sign for investors compared to companies with high cash burn rates.
• The increase in full-year revenue guidance to $78-$80 million indicates strong confidence in future performance, which is a positive signal compared to companies that maintain or lower guidance.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased revenue guidance.
• Employees may benefit from the company's growth and strengthened management team.
• Customers, particularly patients with drug-resistant epilepsy, may benefit from increased access to RNS therapy.
• Suppliers may see increased demand for their products and services due to the company's growth.

Next Steps

• NeuroPace plans to host an investor day in New York during the first quarter of 2025.
• The company looks forward to the publication and presentation of the full results of the Post-Approval Study of the RNS System.
• The company will continue to execute its strategy of increasing access to RNS therapy.

Key Dates

Keywords

NeuroPace, RNS System, Epilepsy, Medical Device, Revenue, Gross Margin, Cash Burn, Financial Results, Guidance, ATM Offering